
    
      The LEGS study is a double blind, placebo-controlled randomised clinical trial using a 2 x 2
      factorial design. Participant will be randomly allocated to one of the four possible
      treatment combinations:

        -  Glucosamine and Chondroitin (double active)

        -  Placebo Glucosamine and Chondroitin

        -  Glucosamine and Placebo Chondroitin

        -  Placebo Glucosamine and Placebo Chondroitin (double placebo)

      Each allocation involves taking 4 study treatment capsules once a day for two years.

      A total of 600 participants with symptomatic knee OA will be recruited by general media
      advertising and by General Practitioners through the New South Wales Divisions of general
      practice.
    
  